FOLK ART GLITTERIFIC Paints

Jasco Pty Limited

Chemwatch Hazard Alert Code: 3

Chemwatch: **7918-40**
Version No: **2.1**
Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

Issue Date: **05/11/2024**
Print Date: **05/11/2024**
L.GHS.AUS.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	FOLK ART GLITTERIFIC Paints
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Paint. Use according to manufacturer's directions.

Details of the manufacturer or supplier of the safety data sheet

Registered company name	**Jasco Pty Limited**
Address	1-5 Commercial Road Kingsgrove NSW 2208 Australia
Telephone	+61 2 9807 1555
Fax	Not Available
Website	www.jasco.com.au
Email	quickinfo@jasco.com.au

Emergency telephone number

Association / Organisation	**Australian Poisons Centre**
Emergency telephone number(s)	**13 11 26 (24/7)**
Other emergency telephone number(s)	**Not Available**

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	Not Applicable
Classification [1]	Flammable Liquids Category 2, Serious Eye Damage/Eye Irritation Category 2A
Legend:	***1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI***

Label elements

Hazard pictogram(s)	
Signal word	**Danger**

Hazard statement(s)

H225	Highly flammable liquid and vapour.
H319	Causes serious eye irritation.
AUH019	May form explosive peroxides.

Precautionary statement(s) Prevention

Page 1 continued...

P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P233	Keep container tightly closed.
P240	Ground and bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/intrinsically safe equipment.
P242	Use non-sparking tools.
P243	Take action to prevent static discharges.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P264	Wash all exposed external body areas thoroughly after handling.

Precautionary statement(s) Response

P370+P378	In case of fire: Use alcohol resistant foam or normal protein foam to extinguish.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337+P313	If eye irritation persists: Get medical advice/attention.
P303+P361+P353	IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower].

Precautionary statement(s) Storage

P403+P235	Store in a well-ventilated place. Keep cool.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
67-63-0	1-10	isopropanol
124-68-5	1-5	monoisobutanolamine
108-01-0	<1	dimethylethanolamine
Not Available	balance	Ingredients determined not to be hazardous
Legend:	***1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available***	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: ▸ Wash out immediately with fresh running water. ▸ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▸ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: ▸ Immediately remove all contaminated clothing, including footwear. ▸ Flush skin and hair with running water (and soap if available). ▸ Seek medical attention in event of irritation.
Inhalation	▸ If fumes or combustion products are inhaled remove from contaminated area. ▸ Lay patient down. Keep warm and rested. ▸ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▸ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▸ Transport to hospital, or doctor.
Ingestion	▸ If swallowed do **NOT** induce vomiting. ▸ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. ▸ Observe the patient carefully. ▸ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. ▸ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. ▸ Seek medical advice.

Indication of any immediate medical attention and special treatment needed

Any material aspirated during vomiting may produce lung injury. Therefore emesis should not be induced mechanically or pharmacologically. Mechanical means should be used if it is considered necessary to evacuate the stomach contents; these include gastric lavage after endotracheal intubation. If spontaneous vomiting has occurred after ingestion, the patient should be monitored for difficult breathing, as adverse effects of aspiration into the lungs may be delayed up to 48 hours.
Treat symptomatically.
To treat poisoning by the higher aliphatic alcohols (up to C7):

- Gastric lavage with copious amounts of water.
- It may be beneficial to instill 60 ml of mineral oil into the stomach.
- Oxygen and artificial respiration as needed.
- Electrolyte balance: it may be useful to start 500 ml. M/6 sodium bicarbonate intravenously but maintain a cautious and conservative attitude toward electrolyte replacement unless shock or severe acidosis threatens.
- To protect the liver, maintain carbohydrate intake by intravenous infusions of glucose.
- Haemodialysis if coma is deep and persistent. [GOSSELIN, SMITH HODGE: Clinical Toxicology of Commercial Products, Ed 5)

Continued...

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 l/min.
- Monitor and treat, where necessary, for shock.
- Monitor and treat, where necessary, for pulmonary oedema.
- Anticipate and treat, where necessary, for seizures.
- **DO NOT** use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.
- Give activated charcoal.

ADVANCED TREATMENT

- Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- If the patient is hypoglycaemic (decreased or loss of consciousness, tachycardia, pallor, dilated pupils, diaphoresis and/or dextrose strip or glucometer readings below 50 mg), give 50% dextrose.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.

EMERGENCY DEPARTMENT

- Laboratory analysis of complete blood count, serum electrolytes, BUN, creatinine, glucose, urinalysis, baseline for serum aminotransferases (ALT and AST), calcium, phosphorus and magnesium, may assist in establishing a treatment regime. Other useful analyses include anion and osmolar gaps, arterial blood gases (ABGs), chest radiographs and electrocardiograph.
- Positive end-expiratory pressure (PEEP)-assisted ventilation may be required for acute parenchymal injury or adult respiratory distress syndrome.
- Acidosis may respond to hyperventilation and bicarbonate therapy.
- Haemodialysis might be considered in patients with severe intoxication.
- Consult a toxicologist as necessary. BRONSTEIN, A.C. and CURRANCE, P.L. EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

For C8 alcohols and above.
Symptomatic and supportive therapy is advised in managing patients.

SECTION 5 Firefighting measures

Extinguishing media

- Alcohol stable foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

Fire Incompatibility	‣ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

Fire Fighting	‣ Alert Fire Brigade and tell them location and nature of hazard. ‣ May be violently or explosively reactive. ‣ Wear breathing apparatus plus protective gloves in the event of a fire. ‣ Prevent, by any means available, spillage from entering drains or water course. ‣ Consider evacuation (or protect in place). ‣ Fight fire from a safe distance, with adequate cover. ‣ If safe, switch off electrical equipment until vapour fire hazard removed. ‣ Use water delivered as a fine spray to control the fire and cool adjacent area. ‣ Avoid spraying water onto liquid pools. ‣ **Do not** approach containers suspected to be hot. ‣ Cool fire exposed containers with water spray from a protected location. ‣ If safe to do so, remove containers from path of fire.
Fire/Explosion Hazard	‣ Liquid and vapour are highly flammable. ‣ Severe fire hazard when exposed to heat, flame and/or oxidisers. ‣ Vapour may travel a considerable distance to source of ignition. ‣ Heating may cause expansion or decomposition leading to violent rupture of containers. ‣ On combustion, may emit toxic fumes of carbon monoxide (CO). Combustion products include: carbon dioxide (CO_2) nitrogen oxides (NO_x) other pyrolysis products typical of burning organic material.
HAZCHEM	•3YE

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	‣ Remove all ignition sources. ‣ Clean up all spills immediately.

Continued...

	▸ Avoid breathing vapours and contact with skin and eyes. ▸ Control personal contact with the substance, by using protective equipment. ▸ Contain and absorb small quantities with vermiculite or other absorbent material. ▸ Wipe up. ▸ Collect residues in a flammable waste container.
Major Spills	▸ Clear area of personnel and move upwind. ▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ May be violently or explosively reactive. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ Consider evacuation (or protect in place). ▸ No smoking, naked lights or ignition sources. ▸ Increase ventilation. ▸ Stop leak if safe to do so. ▸ Water spray or fog may be used to disperse /absorb vapour. ▸ Contain spill with sand, earth or vermiculite. ▸ Use only spark-free shovels and explosion proof equipment. ▸ Collect recoverable product into labelled containers for recycling. ▸ Absorb remaining product with sand, earth or vermiculite. ▸ Collect solid residues and seal in labelled drums for disposal. ▸ Wash area and prevent runoff into drains. ▸ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	▸ Containers, even those that have been emptied, may contain explosive vapours. ▸ Do NOT cut, drill, grind, weld or perform similar operations on or near containers. ▸ **DO NOT** allow clothing wet with material to stay in contact with skin The tendency of many ethers to form explosive peroxides is well documented. Ethers lacking non-methyl hydrogen atoms adjacent to the ether link are thought to be relatively safe ▸ **DO NOT** concentrate by evaporation, or evaporate extracts to dryness, as residues may contain explosive peroxides with DETONATION potential. ▸ Any static discharge is also a source of hazard. ▸ Before any distillation process remove trace peroxides by shaking with excess 5% aqueous ferrous sulfate solution or by percolation through a column of activated alumina. ▸ Distillation results in uninhibited ether distillate with considerably increased hazard because of risk of peroxide formation on storage. ▸ Add inhibitor to any distillate as required. ▸ When solvents have been freed from peroxides by percolation through columns of activated alumina, the absorbed peroxides must promptly be desorbed by treatment with polar solvents such as methanol or water, which should then be disposed of safely. The substance accumulates peroxides which may become hazardous only if it evaporates or is distilled or otherwise treated to concentrate the peroxides. The substance may concentrate around the container opening for example. Purchases of peroxidisable chemicals should be restricted to ensure that the chemical is used completely before it can become peroxidised. ▸ A responsible person should maintain an inventory of peroxidisable chemicals or annotate the general chemical inventory to indicate which chemicals are subject to peroxidation. An expiration date should be determined. The chemical should either be treated to remove peroxides or disposed of before this date. ▸ The person or laboratory receiving the chemical should record a receipt date on the bottle. The individual opening the container should add an opening date. ▸ Unopened containers received from the supplier should be safe to store for 18 months. ▸ Opened containers should not be stored for more than 12 months. ▸ Avoid all personal contact, including inhalation. ▸ Wear protective clothing when risk of exposure occurs. ▸ Use in a well-ventilated area. ▸ Prevent concentration in hollows and sumps. ▸ **DO NOT** enter confined spaces until atmosphere has been checked. ▸ Avoid smoking, naked lights, heat or ignition sources. ▸ When handling, **DO NOT** eat, drink or smoke. ▸ Vapour may ignite on pumping or pouring due to static electricity. ▸ **DO NOT** use plastic buckets. ▸ Earth and secure metal containers when dispensing or pouring product. ▸ Use spark-free tools when handling. ▸ Avoid contact with incompatible materials. ▸ Keep containers securely sealed. ▸ Avoid physical damage to containers. ▸ Always wash hands with soap and water after handling. ▸ Work clothes should be laundered separately. ▸ Use good occupational work practice. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. ▸ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.
Other information	▸ Store in original containers in approved flame-proof area. ▸ No smoking, naked lights, heat or ignition sources. ▸ **DO NOT** store in pits, depression, basement or areas where vapours may be trapped. ▸ Keep containers securely sealed. ▸ Store away from incompatible materials in a cool, dry well ventilated area. ▸ Protect containers against physical damage and check regularly for leaks. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. ▸ Tank storage: Tanks must be specifically designed for use with this product. Bulk storage tanks should be diked (bunded). Locate tanks away from heat and other sources of ignition. Cleaning, inspection and maintenance of storage tanks is a specialist operation, which requires the implementation of strict procedures and precautions. ▸ Keep in a cool place. Electrostatic charges will be generated during pumping. Electrostatic discharge may cause fire. Ensure electrical continuity by bonding and grounding (earthing) all equipment to reduce the risk. The vapours in the head space of the storage vessel may lie in the flammable/explosive range and hence may be flammable. ▸ For containers, or container linings use mild steel, stainless steel. Examples of suitable materials are: high density polyethylene (HDPE), polypropylene (PP), and Viton (FMK), which have been specifically tested for compatibility with this product. ▸ For container linings, use amine-adduct cured epoxy paint. ▸ For seals and gaskets use: graphite, PTFE, Viton A, Viton B. ▸ Unsuitable material: Some synthetic materials may be unsuitable for containers or container linings depending on the material specification and intended use. Examples of materials to avoid are: natural rubber (NR), nitrile rubber (NBR), ethylene propylene rubber

Continued...

	(EPDM), polymethyl methacrylate (PMMA), polystyrene, polyvinyl chloride (PVC), polyisobutylene. However, some may be suitable for glove materials. ▸ Do not cut, drill, grind, weld or perform similar operations on or near containers. Containers, even those that have been emptied, can contain explosive vapours.

Conditions for safe storage, including any incompatibilities

Suitable container	▸ Packing as supplied by manufacturer. ▸ Plastic containers may only be used if approved for flammable liquid. ▸ Check that containers are clearly labelled and free from leaks. ▸ For low viscosity materials (i) : Drums and jerry cans must be of the non-removable head type. (ii) : Where a can is to be used as an inner package, the can must have a screwed enclosure. ▸ For materials with a viscosity of at least 2680 cSt. (23 deg. C) ▸ For manufactured product having a viscosity of at least 250 cSt. (23 deg. C) ▸ Manufactured product that requires stirring before use and having a viscosity of at least 20 cSt (25 deg. C): (i) Removable head packaging; (ii) Cans with friction closures and (iii) low pressure tubes and cartridges may be used. ▸ Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages ▸ In addition, where inner packagings are glass and contain liquids of packing group I there must be sufficient inert absorbent to absorb any spillage, unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.
Storage incompatibility	▸ Avoid reaction with oxidising agents

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	isopropanol	Isopropyl alcohol	400 ppm / 983 mg/m3	1230 mg/m3 / 500 ppm	Not Available	Not Available
Australia Exposure Standards	dimethylethanolamine	Dimethylaminoethanol	2 ppm / 7.4 mg/m3	22 mg/m3 / 6 ppm	Not Available	Not Available

Ingredient	Original IDLH	Revised IDLH
isopropanol	Not Available	Not Available
monoisobutanolamine	Not Available	Not Available
dimethylethanolamine	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
monoisobutanolamine	E	≤ 0.01 mg/m³
Notes:	***Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.***	

MATERIAL DATA

Exposure controls

Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.
The basic types of engineering controls are:
Process controls which involve changing the way a job activity or process is done to reduce the risk.
Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.
Employers may need to use multiple types of controls to prevent employee overexposure.
For flammable liquids and flammable gases, local exhaust ventilation or a process enclosure ventilation system may be required. Ventilation equipment should be explosion-resistant.
Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be

Continued...

	a minimum of 1-2 m/s (200-400 f/min.) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used. · Adequate ventilation is typically taken to be that which limits the average concentration to no more than 25% of the LEL within the building, room or enclosure containing the dangerous substance. · Ventilation for plant and machinery is normally considered adequate if it limits the average concentration of any dangerous substance that might potentially be present to no more than 25% of the LEL. However, an increase up to a maximum 50% LEL can be acceptable where additional safeguards are provided to prevent the formation of a hazardous explosive atmosphere. For example, gas detectors linked to emergency shutdown of the process might be used together with maintaining or increasing the exhaust ventilation on solvent evaporating ovens and gas turbine enclosures. · Temporary exhaust ventilation systems may be provided for non-routine higher-risk activities, such as cleaning, repair or maintenance in tanks or other confined spaces or in an emergency after a release. The work procedures for such activities should be carefully considered.. The atmosphere should be continuously monitored to ensure that ventilation is adequate and the area remains safe. Where workers will enter the space, the ventilation should ensure that the concentration of the dangerous substance does not exceed 10% of the LEL (irrespective of the provision of suitable breathing apparatus)
Individual protection measures, such as personal protective equipment	
Eye and face protection	▸ Safety glasses with side shields. ▸ Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent] ▸ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].
Skin protection	See Hand protection below
Hands/feet protection	▸ Wear chemical protective gloves, e.g. PVC. ▸ Wear safety footwear or safety gumboots, e.g. Rubber The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application. The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice. Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: · frequency and duration of contact, · chemical resistance of glove material, · glove thickness and · dexterity Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent). · When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use. · Contaminated gloves should be replaced. As defined in ASTM F-739-96 in any application, gloves are rated as: · Excellent when breakthrough time > 480 min · Good when breakthrough time > 20 min · Fair when breakthrough time < 20 min · Poor when glove material degrades For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended. It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times. Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example: · Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of. · Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
Body protection	See Other protection below
Other protection	▸ Overalls. ▸ PVC Apron. ▸ PVC protective suit may be required if exposure severe. ▸ Eyewash unit. ▸ Ensure there is ready access to a safety shower. ▸ Some plastic personal protective equipment (PPE) (e.g. gloves, aprons, overshoes) are not recommended as they may produce static electricity. ▸ For large scale or continuous use wear tight-weave non-static clothing (no metallic fasteners, cuffs or pockets). ▸ Non sparking safety or conductive footwear should be considered. Conductive footwear describes a boot or shoe with a sole made from a conductive compound chemically bound to the bottom components, for permanent control to electrically ground the foot an shall dissipate static electricity from the body to reduce the possibility of ignition of volatile compounds. Electrical resistance must range between 0 to 500,000 ohms. Conductive shoes should be stored in lockers close to the room in which they are worn. Personnel who have been issued conductive footwear should not wear them from their place of work to their homes and return.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".

Respiratory protection

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Continued...

The effect(s) of the following substance(s) are taken into account in the ***computer-generated*** selection:
FOLK ART GLITTERIFIC Paints

Material	CPI
BUTYL	C
NAT+NEOPR+NITRILE	C
NATURAL RUBBER	C
NATURAL+NEOPRENE	C
NEOPRENE	C
NITRILE	C
NITRILE+PVC	C
PE/EVAL/PE	C
PVC	C

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Ansell Glove Selection

Glove — *In order of recommendation*
AlphaTec® 58-530B
AlphaTec® 58-530W
AlphaTec® 79-700
AlphaTec® Solvex® 37-675
MICROFLEX® 63-864
MICROFLEX® Diamond Grip® MF-300
TouchNTuff® 83-500
AlphaTec® Solvex® 37-185
AlphaTec® 38-612
AlphaTec® 58-008

The suggested gloves for use should be confirmed with the glove supplier.

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AK-AUS P2	-	AK-PAPR-AUS / Class 1 P2
up to 50 x ES	-	AK-AUS / Class 1 P2	-
up to 100 x ES	-	AK-2 P2	AK-PAPR-2 P2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Highly flammable liquid.

Physical state	Liquid	**Relative density (Water = 1)**	Not Available
Odour	Not Available	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Available
pH (as supplied)	Not Available	**Decomposition temperature (°C)**	Not Available
Melting point / freezing point (°C)	Not Available	**Viscosity (cSt)**	Not Available
Initial boiling point and boiling range (°C)	Not Available	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	*11.7 (isopropanol)	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	HIGHLY FLAMMABLE.	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Available	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Available	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	Not Available	**Gas group**	Not Available
Solubility in water	Not Available	**pH as a solution (1%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	Not Available
Heat of Combustion (kJ/g)	Not Available	**Ignition Distance (cm)**	Not Available
Flame Height (cm)	Not Available	**Flame Duration (s)**	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	**Enclosed Space Ignition Deflagration Density (g/m3)**	Not Available

Continued...

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	▸ Unstable in the presence of incompatible materials. ▸ Product is considered stable. ▸ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may be damaging to the health of the individual. Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Exposure to aliphatic alcohols with more than 3 carbons may produce central nervous system effects such as headache, dizziness, drowsiness, muscle weakness, delirium, CNS depression, coma, seizure, and neurobehavioural changes. Symptoms are more acute with higher alcohols. Respiratory tract involvement may produce irritation of the mucosa, respiratory insufficiency, respiratory depression secondary to CNS depression, pulmonary oedema, chemical pneumonitis and bronchitis. Cardiovascular involvement may result in arrhythmias and hypotension. Gastrointestinal effects may include nausea and vomiting. Kidney and liver damage may result following massive exposures. The alcohols are potential irritants being, generally, stronger irritants than similar organic structures that lack functional groups (e.g. alkanes) but are much less irritating than the corresponding amines, aldehydes or ketones. Alcohols and glycols (diols) rarely represent serious hazards in the workplace, because their vapour concentrations are usually less than the levels which produce significant irritation which, in turn, produce significant central nervous system effects as well. The odour of isopropanol may give some warning of exposure, but odour fatigue may occur. Inhalation of isopropanol may produce irritation of the nose and throat with sneezing, sore throat and runny nose. The effects in animals subject to a single exposure, by inhalation, included inactivity or anaesthesia and histopathological changes in the nasal canal and auditory canal.
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. The main features defining a nootropic drugs (cognitive enhancers) are: ▸ the enhancement of learning and memory acquisition ▸ protection of the brain against various physical or chemical injury ▸ facilitation of flow of information between the hemispheres of the brain ▸ absence of usual negative effects of psychotropic drugs particularly central nervous system toxicity. Extensive study of the modes of action of the nootropics reveals certain pharmacological effects There appears to be no single predominant mode of action shared by the whole class of drugs, however all influence cholinergic function. By increasing high affinity choline uptake these drugs facilitate acetylcholine production and turnover with various actions at both muscarinic and nicotinic receptors (there is a serious decline in acetylcholine reception in aged humans). Occasional side-effects may include nausea, vomiting, headache, blurred vision, skin rashes, nasal stuffiness, flushing of the skin, dizziness, bradycardia and orthostatic hypotension. Cardiovascular effects may include sinus bradycardia. Effects on the nervous system characterise over-exposure to higher aliphatic alcohols. These include headache, muscle weakness, giddiness, ataxia, (loss of muscle coordination), confusion, delirium and coma. Gastrointestinal effects may include nausea, vomiting and diarrhoea. In the absence of effective treatment, respiratory arrest is the most common cause of death in animals acutely poisoned by the higher alcohols. Aspiration of liquid alcohols produces an especially toxic response as they are able to penetrate deeply in the lung where they are absorbed and may produce pulmonary injury. Those possessing lower viscosity elicit a greater response. The result is a high blood level and prompt death at doses otherwise tolerated by ingestion without aspiration. In general the secondary alcohols are less toxic than the corresponding primary isomers. As a general observation, alcohols are more powerful central nervous system depressants than their aliphatic analogues. In sequence of decreasing depressant potential, tertiary alcohols with multiple substituent OH groups are more potent than secondary alcohols, which, in turn, are more potent than primary alcohols. The potential for overall systemic toxicity increases with molecular weight (up to C7), principally because the water solubility is diminished and lipophilicity is increased. Within the homologous series of aliphatic alcohols, narcotic potency may increase even faster than lethality Only scanty toxicity information is available about higher homologues of the aliphatic alcohol series (greater than C7) but animal data establish that lethality does not continue to increase with increasing chain length. Aliphatic alcohols with 8 carbons are less toxic than those immediately preceding them in the series. 10 -Carbon n-decyl alcohol has low toxicity as do the solid fatty alcohols (e.g. lauryl, myristyl, cetyl and stearyl). However the rat aspiration test suggests that decyl and melted dodecyl (lauryl) alcohols are dangerous if they enter the trachea. In the rat even a small quantity (0.2 ml) of these behaves like a hydrocarbon solvent in causing death from pulmonary oedema. Primary alcohols are metabolised to corresponding aldehydes and acids; a significant metabolic acidosis may occur. Secondary alcohols are converted to ketones, which are also central nervous system depressants and which, in he case of the higher homologues persist in the blood for many hours. Tertiary alcohols are metabolised slowly and incompletely so their toxic effects are generally persistent. Swallowing 10 millilitres of isopropanol may cause serious injury; 100 millilitres may be fatal if not properly treated. The adult single lethal dose is approximately 250 millilitres. Isopropanol is twice as poisonous as ethanol, and the effects caused are similar, except that isopropanol does not cause an initial feeling of well-being. Swallowing may cause nausea, vomiting and diarrhea; vomiting and stomach inflammation is more prominent with isopropanol than with ethanol. Animals given near-lethal doses also showed inco-ordination, lethargy, inactivity and loss of consciousness. There is evidence that a slight tolerance to isopropanol may be acquired.
Skin Contact	Repeated exposure may cause skin cracking, flaking or drying following normal handling and use. Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

Continued...

	Most liquid alcohols appear to act as primary skin irritants in humans. Significant percutaneous absorption occurs in rabbits but not apparently in man. For isopropanol (IPA): Acute toxicity: Isopropanol has a low order of acute toxicity. It is irritating to the eyes, but not to the skin. Very high vapor concentrations are irritating to the eyes, nose, and throat, and prolonged exposure may produce central nervous system depression and narcosis. Human volunteers reported that exposure to 400 ppm isopropanol vapors for 3 to 5 min. caused mild irritation of the eyes, nose and throat. Although isopropanol produced little irritation when tested on the skin of human volunteers, there have been reports of isolated cases of dermal irritation and/or sensitization. The use of isopropanol as a sponge treatment for the control of fever has resulted in cases of intoxication, probably the result of both dermal absorption and inhalation. There have been a number of cases of poisoning reported due to the intentional ingestion of isopropanol, particularly among alcoholics or suicide victims. These ingestions typically result in a comatose condition. Pulmonary difficulty, nausea, vomiting, and headache accompanied by various degrees of central nervous system depression are typical. In the absence of shock, recovery usually occurred. Repeat dose studies: The systemic (non-cancer) toxicity of repeated exposure to isopropanol has been evaluated in rats and mice by the inhalation and oral routes. The only adverse effects-in addition to clinical signs identified from these studies were to the kidney. Reproductive toxicity: A recent two-generation reproductive study characterised the reproductive hazard for isopropanol associated with oral gavage exposure. This study found that the only reproductive parameter apparently affected by isopropanol exposure was a statistically significant decrease in male mating index of the F1 males. It is possible that the change in this reproductive parameter was treatment related and significant, although the mechanism of this effect could not be discerned from the results of the study. However, the lack of a significant effect of the female mating index in either generation, the absence of any adverse effect on litter size, and the lack of histopathological findings of the testes of the high-dose males suggest that the observed reduction in male mating index may not be biologically meaningful. Developmental toxicity: The developmental toxicity of isopropanol has been characterized in rat and rabbit developmental toxicity studies. These studies indicate that isopropanol is not a selective developmental hazard. Isopropanol produced developmental toxicity in rats, but not in rabbits. In the rat, the developmental toxicity occurred only at maternally toxic doses and consisted of decreased foetal body weights, but no teratogenicity Genotoxicity: All genotoxicity assays reported for isopropanol have been negative Carcinogenicity: rodent inhalation studies were conduct to evaluate isopropanol for cancer potential. The only tumor rate increase seen was for interstitial (Leydig) cell tumors in the male rats. Interstitial cell tumors of the testis is typically the most frequently observed spontaneous tumor in aged male Fischer 344 rats. These studies demonstrate that isopropanol does not exhibit carcinogenic potential relevant to humans. Furthermore, there was no evidence from this study to indicate the development of carcinomas of the testes in the male rat, nor has isopropanol been found to be genotoxic. Thus, the testicular tumors seen in the isopropanol exposed male rats are considered of no significance in terms of human cancer risk assessment
Eye	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.
Chronic	On the basis, primarily, of animal experiments, concern has been expressed by at least one classification body that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. Studies with some glycol ethers (principally the monoethylene glycols) and their esters indicate reproductive changes, testicular atrophy, infertility and kidney function changes. The metabolic acetic acid derivatives of glycol ethers (alkoxyacetic acids), not the ether itself, have been found to be the proximal reproductive toxin in animals. The potency of these metabolites decreases significantly as the chain length of the ether increases. Consequently glycol ethers with longer substituents (e.g diethylene glycols, triethylene glycols) have not generally been associated with reproductive effects. One of the most sensitive indicators of toxic effects observed from many of the glycol ethers is an increase in the erythrocytic osmotic fragility in rats Which produces haemolytic anaemia). This appears to be related to the development of haemoglobinuria (blood in the urine) at higher exposure levels or as a result of chronic exposure. Glycol ethers based on propylene oxides, propylene glycol ethers, dipropylene glycol ethers and tripropylene glycol ethers are mainly available, commercially, as alpha-isomers (because of thermodynamic considerations); these are incapable of forming alkoxyacetic or alkoxypropionic acids as metabolites and therefore do not produce erythrocyte fragility unless contaminated by ethylene glycol ethers or to a significant degree by the beta-isomer . beta-Isomers are able to form the alkoxypropionic acids and these are linked to teratogenic effects (and possibly haemolytic effects). Long term, or repeated exposure of isopropanol may cause inco-ordination and tiredness. Repeated inhalation exposure to isopropanol may produce sleepiness, inco-ordination and liver degeneration. Animal data show developmental effects only at exposure levels that produce toxic effects in adult animals. Isopropanol does not cause genetic damage. There are inconclusive reports of human sensitisation from skin contacts with isopropanol. Chronic alcoholics are more tolerant of the whole-body effects of isopropanol. Animal testing showed the chronic exposure did not produce reproductive effects. NOTE: Commercial isopropanol does not contain "isopropyl oil", which caused an excess incidence of sinus and throat cancers in isoproanol production workers in the past. "Isopropyl oil" is no longer formed during production of isopropanol.

FOLK ART GLITTERIFIC Paints	**TOXICITY**	**IRRITATION**
	Not Available	Not Available

isopropanol	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: 12800 mg/kg[2]	Eye (Rodent - rabbit): 100mg - Severe
	Inhalation (Mouse) LC50: 53 mg/L4h[2]	Eye (Rodent - rabbit): 100mg/24H - Moderate
	Oral (Mouse) LD50; 3600 mg/kg[2]	Eye (Rodent - rabbit): 10mg - Moderate
		Eye: adverse effect observed (irritating)[1]
		Skin (Rodent - rabbit): 500mg - Mild
		Skin: no adverse effect observed (not irritating)[1]

monoisobutanolamine	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >2000 mg/kg[1]	Eye: adverse effect observed (irreversible damage)[1]
	Oral (Mouse) LD50; 2150 mg/kg[2]	Skin: adverse effect observed (irritating)[1]

dimethylethanolamine	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: 1219 mg/kg[1]	Eye (Rodent - rabbit): 5uL - Severe
	Inhalation (Mouse) LC50: 3.25 mg/L4h[2]	Eye: adverse effect observed (irreversible damage)[1]
	Oral (Rat) LD50: 1182.7 mg/kg[1]	Skin (Rodent - rabbit): 445mg - Mild
		Skin: adverse effect observed (corrosive)[1]

Continued...

	Skin: adverse effect observed (irritating)[1]

Legend:	***1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances***

ISOPROPANOL	For isopropanol (IPA): **Acute toxicity:** Isopropanol has a low order of acute toxicity. It is irritating to the eyes, but not to the skin. Very high vapor concentrations are irritating to the eyes, nose, and throat, and prolonged exposure may produce central nervous system depression and narcosis. Human volunteers reported that exposure to 400 ppm isopropanol vapors for 3 to 5 min. caused mild irritation of the eyes, nose and throat. Although isopropanol produced little irritation when tested on the skin of human volunteers, there have been reports of isolated cases of dermal irritation and/or sensitization. The use of isopropanol as a sponge treatment for the control of fever has resulted in cases of intoxication, probably the result of both dermal absorption and inhalation. There have been a number of cases of poisoning reported due to the intentional ingestion of isopropanol, particularly among alcoholics or suicide victims. These ingestions typically result in a comatose condition. Pulmonary difficulty, nausea, vomiting, and headache accompanied by various degrees of central nervous system depression are typical. In the absence of shock, recovery usually occurred. **Repeat dose studies**: The systemic (non-cancer) toxicity of repeated exposure to isopropanol has been evaluated in rats and mice by the inhalation and oral routes. The only adverse effects-in addition to clinical signs identified from these studies were to the kidney. **Reproductive toxicity**: A recent two-generation reproductive study characterised the reproductive hazard for isopropanol associated with oral gavage exposure. This study found that the only reproductive parameter apparently affected by isopropanol exposure was a statistically significant decrease in male mating index of the F1 males. It is possible that the change in this reproductive parameter was treatment related and significant, although the mechanism of this effect could not be discerned from the results of the study. However, the lack of a significant effect of the female mating index in either generation, the absence of any adverse effect on litter size, and the lack of histopathological findings of the testes of the high-dose males suggest that the observed reduction in male mating index may not be biologically meaningful. **Developmental toxicity:** The developmental toxicity of isopropanol has been characterized in rat and rabbit developmental toxicity studies. These studies indicate that isopropanol is not a selective developmental hazard. Isopropanol produced developmental toxicity in rats, but not in rabbits. In the rat, the developmental toxicity occurred only at maternally toxic doses and consisted of decreased foetal body weights, but no teratogenicity **Genotoxicity:** All genotoxicity assays reported for isopropanol have been negative **Carcinogenicity:** rodent inhalation studies were conduct to evaluate isopropanol for cancer potential. The only tumor rate increase seen was for interstitial (Leydig) cell tumors in the male rats. Interstitial cell tumors of the testis is typically the most frequently observed spontaneous tumor in aged male Fischer 344 rats. These studies demonstrate that isopropanol does not exhibit carcinogenic potential relevant to humans. Furthermore, there was no evidence from this study to indicate the development of carcinomas of the testes in the male rat, nor has isopropanol been found to be genotoxic. Thus, the testicular tumors seen in the isopropanol exposed male rats are considered of no significance in terms of human cancer risk assessment The substance is classified by IARC as Group 3: **NOT** classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.
MONOISOBUTANOLAMINE	For tris(hydroxymethyl)aminomethane (TRIS AMINO; CAS 77-88-1) and its surrogates 2-amino-2-methyl-1,3-propanediol (AMPD; CAS 115-69-5) and monoisobutanolamine (AMP; CAS 124-68-5) TRIS AMINO and the surrogate chemicals have displayed little if any toxicity to humans during their long history of use as human drugs and/or in personal care products and cosmetics. TRIS AMINO has found use as an IV drug for the management of acidosis in humans for many years and the toxicity of AMPD and AMP have been reviewed by the Cosmetic Ingredient Review Expert Panel which concluded that these materials are safe as used in cosmetic formulations up to 1% **Acute toxicity:** Mammalian toxicity studies have displayed similar results. The oral LD50 value for TRIS AMINO is 5500 mg/kg in the mouse, and its surrogates range from 2150 to greater than 5000 mg/kg in the rat and mouse. TRIS AMINO was non-irritating to eyes when a 40% aqueous solution was applied to the eyes of rabbits (pH 10.4 for 0.1M aqueous solution). In contrast, 95% AMP in water was severely irritating to the eyes, presumably due to the severely alkaline pH of the test solution used (pH 11.3 for 0.1M aqueous solution); however, more neutral cosmetic formulations containing lower concentrations of AMP are only minimally irritating. There is no sensitisation data available for TRIS AMINO; however, based on the following data, TRIS AMINO is not expected to be a sensitiser. Laboratory animal test samples of AMP did not cause allergic skin reactions when tested in guinea pigs following topical or intradermal administration. In patch tests with humans, AMP and cosmetic formulations containing either AMP or AMPD were negative for dermal sensitisation. **Repeated dose toxicity**: Repeated-dose mammalian toxicity studies conducted on TRIS AMINO and the two surrogate chemicals indicate that the compounds are generally well-tolerated at concentrations as high as 500 mg/kg/day via IV infusion for TRIS AMINO and ingestion of up to 3200 ppm in the rodent diet (250-750 mg/kg/day for rats and mice, estimated). A number of human clinical trials of the IV infusion of TRIS AMINO have also been successfully conducted. In all studies, the only target tissue, when observed at all, has been the liver with AMP. Human clinical studies with Keterolac(a major component of which is TRIS AMINO) have suggested that patients with decreased liver function not be given the drug over extended treatment periods based upon changes in several clinical chemistry parameters. Ingestion of relatively high dosages of AMP has caused liver histopathological changes in rats and dogs. The most significant toxicological activity has been a foetotoxic effect of AMP when ingested at relatively high levels by pregnant rats. Subsequent dermal exposure to comparable dosages failed to elicit a developmental effect in rats. Overall, there have been no consistently-noted observations or treatment-related findings among the numerous repeated-dose mammalian toxicity studies that have been conducted over at last 50 years on these compounds that would indicate long-term significant toxicity of either compound at typical human exposure levels. Reflective of these findings is the fact that both TRIS AMINO and AMP display similar patterns of excretion from the body, being primarily eliminated unchanged via the urine over a relatively short period of time. Further, no evidence of either direct reactivity or metabolism to reactive species toward genetic material has been observed. **Genetic toxicity:** Studies conducted on the TRIS AMINO and the surrogate substances in the presence or absence of mammalian metabolic enzymes have all been negative.
DIMETHYLETHANOLAMINE	Dimethylaminoethanol pyroglutamate increased choline and acetylcholine extracellular levels in the brain's prefrontal cortex in vivo in rat experiments. It further improved spatial memory and reduced scopolamine-induced memory deficits [46]. Dimethylaminoethanol cyclohexyl carboxylate fumarate significantly enhanced working memory performance in rats in the radial arm maze According to an electroencephalogram (EEG) analysis, supplements combining vitamins and minerals with compounds containing DMAE in humans for three months showed increased alertness, attention, and overall mood improvement [48]. DMAE also improved sleep quality and was able to induce lucid dreams]. Its administration has been tested in child hyperkinetic syndrome [50] and minimal brain dysfunction syndrome THe daily dosage should be 500–2000 mg in the form of DMAE bitartrate. It is contraindicated during pregnancy, lactation, and in patients with schizophrenia While it is difficult to generalise about the full range of potential health effects posed by exposure to the many different amine compounds, characterised by those used in the manufacture of polyurethane and polyisocyanurate foams, it is agreed that overexposure to the majority of these materials may cause adverse health effects. ▸ Many amine-based compounds can induce histamine liberation, which, in turn, can trigger allergic and other physiological effects, including bronchoconstriction or bronchial asthma and rhinitis. ▸ Systemic symptoms include headache, nausea, faintness, anxiety, a decrease in blood pressure, tachycardia (rapid heartbeat), itching, erythema (reddening of the skin), urticaria (hives), and facial edema (swelling). Systemic effects (those affecting the body) that are related to the pharmacological action of amines are usually transient. Typically, there are four routes of possible or potential exposure: inhalation, skin contact, eye contact, and ingestion. **Inhalation:** Inhalation of vapors may, depending upon the physical and chemical properties of the specific product and the degree and length of exposure, result in moderate to severe irritation of the tissues of the nose and throat and can irritate the lungs. Products with higher vapour pressures have a greater potential for higher airborne concentrations. This increases the probability of worker exposure.

Continued...

Higher concentrations of certain amines can produce severe respiratory irritation, characterised by nasal discharge, coughing, difficulty in breathing, and chest pains.
Chronic exposure via inhalation may cause headache, nausea, vomiting, drowsiness, sore throat, bronchopneumonia, and possible lung damage. Also, repeated and/or prolonged exposure to some amines may result in liver disorders, jaundice, and liver enlargement. Some amines have been shown to cause kidney, blood, and central nervous system disorders in laboratory animal studies.
While most polyurethane amine catalysts are not sensitisers, some certain individuals may also become sensitized to amines and may experience respiratory distress, including asthma-like attacks, whenever they are subsequently exposed to even very small amounts of vapor. Once sensitised, these individuals must avoid any further exposure to amines. Although chronic or repeated inhalation of vapor concentrations below hazardous or recommended exposure limits should not ordinarily affect healthy individuals, chronic overexposure may lead to permanent pulmonary injury, including a reduction in lung function, breathlessness, chronic bronchitis, and immunologic lung disease.
Inhalation hazards are increased when exposure to amine catalysts occurs in situations that produce aerosols, mists, or heated vapors. Such situations include leaks in fitting or transfer lines. Medical conditions generally aggravated by inhalation exposure include asthma, bronchitis, and emphysema.
Skin Contact:
Skin contact with amine catalysts poses a number of concerns. Direct skin contact can cause moderate to severe irritation and injury-i.e., from simple redness and swelling to painful blistering, ulceration, and chemical burns. Repeated or prolonged exposure may also result in severe cumulative dermatitis.
Skin contact with some amines may result in allergic sensitisation. Sensitised persons should avoid all contact with amine catalysts.
Systemic effects resulting from the absorption of the amines through skin exposure may include headaches, nausea, faintness, anxiety, decrease in blood pressure, reddening of the skin, hives, and facial swelling. These symptoms may be related to the pharmacological action of the amines, and they are usually transient.
Eye Contact:
Amine catalysts are alkaline in nature and their vapours are irritating to the eyes, even at low concentrations.
Direct contact with the liquid amine may cause severe irritation and tissue injury, and the “burning” may lead to blindness. (Contact with solid products may result in mechanical irritation, pain, and corneal injury.)
Exposed persons may experience excessive tearing, burning, conjunctivitis, and corneal swelling.
The corneal swelling may manifest itself in visual disturbances such as blurred or “foggy” vision with a blue tint (“blue haze”) and sometimes a halo phenomenon around lights. These symptoms are transient and usually disappear when exposure ceases.
Some individuals may experience this effect even when exposed to concentrations below doses that ordinarily cause respiratory irritation.
Ingestion:
The oral toxicity of amine catalysts varies from moderately to very toxic.
Some amines can cause severe irritation, ulceration, or burns of the mouth, throat, esophagus,and gastrointestinal tract.
Material aspirated (due to vomiting) can damage the bronchial tubes and the lungs.
Affected persons also may experience pain in the chest or abdomen, nausea, bleeding of the throat and the gastrointestinal tract, diarrhea, dizziness, drowsiness, thirst, circulatory collapse, coma, and even death.
Polyurethane Amine Catalysts: Guidelines for Safe Handling and Disposal; Technical Bulletin June 2000
Alliance for Polyurethanes Industry
For dimethylethanolamine (DMAE) and selected salts and esters:
Toxicology:
Humans: 10 to 20 mg (0.042-0.084 mmol) of DMAE tartrate administered orally to humans, produced mild mental stimulation. At 20 mg/day (0.084 mmol), there was a gradual increase in muscle tone and perhaps an increased frequency of convulsions in susceptible individuals. Larger doses (not specified) produced insomnia, muscle tenseness, and spontaneous muscle twitches.
Doses of DMAE as high as 1200 mg/day (13.46 mmol/day) produced no serious side effects. A single 2500-mg (27.80-mmol) dose taken in a suicide attempt had no adverse effect. A single 2500-mg (27.80-mmol) dose taken in a suicide attempt had no adverse effect.
DMAE supplementation is contraindicated during pregnancy and lactation It is also contraindicated for treatment of people with symptoms of schizophrenia and clonic-tonic seizure disorders The principal contraindication to the use of DMAE was grand mal epilepsy. DMAE also antagonizes the depressant effects of barbiturates.
A large number of adverse health effects are associated with DMAE. These include cardiovascular, neurological, and/or psychological effects. Specific attribution of adverse effects to DMAE is unlikely, as many of these products also contained Ephedra vulgaris alkaloids and other Ephedra spp. Ephedra alkaloids cause similar cardiovascular and neurological effects reported for DMAE.
DMAE, thought to be a precursor for acetylcholine, has been tested for its efficacy in treating a variety of diseases possibly related to deficiencies of acetylcholine, including tardive dyskinesia, Alzheimer's disease, amnesic disorders, age-related cognitive impairment, and Tourette's syndrome, with mixed results . Treatment with DMAE for tardive dyskinesia, a side effect of neuroleptic medications, was associated with serious cholinergic side effects: nasal and oral secretions, dyspnea, and respiratory failure . DMAE was used in the treatment of one patient for a low-frequency action tremor. This treatment was successful for ten years, until side effects of increasing neck pain and orofacial and respiratory dyskinesia occurred. Treatment was discontinued, and it was concluded that the dyskinesia could be attributed to the effects of DMAE.
A meta-analysis of randomized controlled trials indicated that DMAE was no more effective than placebo in the treatment of tardive dyskinesia. Rather, there was a significantly increased risk of adverse events associated with the DMAE treatment.
DMAE treatment increases in the concentration of choline in both the plasma and the brain of treated rats; the mechanism for this phenomenon was unknown. Since it was known that DMAE inhibits the influx of choline to the brain across the blood brain barrier, it is possible that DMAE also inhibited the efflux of choline from the brain, resulting in an accumulation in the brain.
Differential penetration of the blood-brain barrier by several DMAE derivatives has been noted. Radiolabeled DMAE p-chlorophenoxyacetate was found in higher concentrations in the brain than radiolabeled DMAE after intravenous treatment of mice. Higher levels of DMAE were found in the brain after dosing with centrophenoxine than with DMAE, possibly due to improved penetration of the blood-brain barrier by the esterified form of DMAE. Similarly radiolabeled cyprodenate maleate (the cyclohexylpropionic acid ester of DMAE) was more rapidly absorbed and accumulated to a large extent in the brain.
Choline, or trimethylaminoethanol, may be formed by methylation of DMAE . Choline is an essential nutrient. Although small amounts may be synthesised, choline must be supplemented through the diet to maintain adequate physiological concentrations for optimal health. Choline is a precursor for the neurotransmitter, acetylcholine. As a possible precursor of choline, DMAE has also been studied as a potential modulator of many biological processes requiring choline; these include the production of structural components of cell membranes (the phospholipids, especially phosphatidylcholine and sphingomyelin), the synthesis of intracellular signalling molecules (diacylglycerol and ceramide) , platelet activating factor and spingophosphorylcholine. Phosphatidylcholine is a required component of very low-density lipoproteins (VLDL) particles, necessary for the transportation of cholesterol and fat from the liver to other sites in the body. Betaine, a metabolite of choline, participates in methyl-group transfer.
In one occupational study in the manufacture of polyurethane foam insulation for refrigerators, adverse effects included disorders of the upper respiratory tract and nervous system, along with significant changes in the immune status of workers exposed to a mixture of DMAE, ethylenediamine, propylene oxide, and 4,4'-methylenediphenyl diisocyanate . A spray painter developed severe respiratory symptoms, which seemed to be related to occupational exposure to a specific type of spray paint containing DMAE. Follow-on skin tests with DMAE (undiluted, and 1:10 and 1:100 dilutions in saline) in three human volunteers produced wheal and flare responses at the high dose. This was interpreted as an irritant response, and not a sign of immunotoxicity . Despite one clear case for occupational asthma form DMAE exposure, it fails to meet the current criteria for classification as a respiratory sensitiser
Neurotoxicity: Using a method to classify the risks associated with occupational exposures to neurotoxic chemicals obtained from four national computer-based registers, DMAE produces a small increase in the risk of damaging the nervous system under normal work conditions.
DMAE (as centrophenoxine, an ester of DMAE)) was tested for its effects on spinal reflexes in mice. 50 mg/kg (0.170 mmol/kg) demonstrated a considerable change in spinal reflexes, specifically in the inhibition of polysynaptic reflexes. Higher doses (400 to 600 mg/kg [1.40 to 2.04 mmol/kg] intraperitoneally) resulted in ataxia, reduced mobility, inhibition, and mortality in some treated mice. Similar doses in rats resulted in limited mobility and an inhibited state.
Intravenous administration of DMAE (175 to 350 mg/kg; 1.95 to 3.90 mmol/kg) resulted in dose-dependant psychoanaleptic effects (as demonstrated by spontaneous running in mice) and an influence on conditioned reflexes in rats.
DMAE appears to exert a central vasomotor stimulant effect. Intracerebroventricular (ICV) administration of DMAE (0.1 to 2.0 mg; 1.0 to 20 umol) resulted in potentiation of the carotid occlusion response (all doses) resulting in an increase in blood pressure in dogs (higher doses).

Continued...

	This effect was not abolished by atropine sulfate (ICV). With meclofenoxate (centrophenoxine hydrochloride) treatment (10 to 40 mg/kg body weight; 0.040 to 0.16 mmol/kg), a significant dose-dependent reduction in both blood pressure (up to 49.7+/-0.39 mmHg reduction) and heart rate (up to 71 +/-4.5% reduction) was observed in the old rats at the 40 mg/kg (0.16 mmol/kg) dose level **Reproductive toxicity:** No histopathological changes in the gonads were observed after repeated exposure to DMAE in a 90-day inhalation study in rats DMAE via inhalation induced maternal toxicity in rats at all tested exposure levels (10, 30, and 100 ppm; 40, 110, and 370 mg/m3; 0.41, 1.20, and 4.10 mmol/m3), as demonstrated by changes in body weight gain in the mid- and high-dose groups and ocular changes in the mid- and low-dose. Sporadic, inconsistent alterations in gestational parameters including significant decreases in viable implants per litter, percentage live foetuses/litter, and litter size in rats exposed to 10 ppm (40 mg/m3; 41 mmol/m3) and a significant decrease in the percentage of male foetuses in rats exposed to 30 ppm (110 mg/m3; 1.20 mmol/m3). Skeletal variations in foetuses included decreased incidences of poorly ossified cervical centrum , bilobed thoracic centrum , bilobed sternebrae ,unossified proximal phalanges of the forelimb, and increased incidences of split cervical centra ,and bilobed thoracic centrum . However, a consistent pattern was lacking, resulting in a NOAEL for embryofoetal toxicity and teratogenicity of 100 ppm (370 mg/m3; 4.10 mmol/m3) or greater. A NOAEL for maternal toxicity was estimated at 10 ppm (40 mg/m3; 0.41 mmol/m3). A five-generation study was conducted; each generation of rats or only the first and fifth generations were exposed in utero to centrophenoxine on gestation days 11 to 14 (during embryogenesis), Treating Wistar dams with meclofenoxate prenatally resulted in significant increases in weight of the offspring. The increase in embryo weights did not continue into postnatal life. Continuous treatment through several generations increased fertility and an overall increase in the number of offspring Carcinogenicity: There was no statistically significant increase, or morphological difference, in the incidence of neoplasms in any organ in female C3H/HeN mice given drinking water with 10 mM (900 ug/mL) DMAE for 105 weeks, or in female C3H/HeJ(+) mice given 15 mM (1300 ug/mL) DMAE for 123 weeks . No changes in the structure, appearance, or microscopic morphology of various organs were observed. Treatment with DMAE did not affect survival, initial body weight gain, or mature body weight of either strain of mouse Di- and triaminoethanols, which are structurally related to DMAE and are found in cutting fluids, pesticides, and cosmetics, can give rise to N-nitrosodiethanolamine (NDELA) via nitrosation resulting from reaction with nitrite or nitrous oxide. The authors also noted that NDELA has been shown to be a potent carcinogen, producing mainly hepatocellular carcinomas in rats and epithelial neoplasms of the nasal cavity and trachea in hamsters. **Genotoxicity:** Salmonella typhimurium assay. Tester strains TA98, TA100, TA1535, TA1537, and TA1538 were all tested, both in the presence and absence of a metabolic activation system. DMAE, ranging from 0.37 to 995 umol (0.033 to 89.5 mg)/plate failed to demonstrate any mutagenic response. DMAE also failed to induce any sex-linked recessive lethal mutations in the Drosophila melanogaster (7200 or 8100 ppm; 80.10 or 90.10 mmol/L). The genotoxicity of DMAE was investigated in several mammalian systems, both in vitro and in vivo. In vitro assays included sister chromatid exchange and hypoxanthine-guanine phosphoribosyl transferase forward gene mutation test (HGPT), both in Chinese hamster ovary cells. All of the in vitro assays failed to demonstrate genotoxicity within the dose ranges.. Immunotoxicity: DMAE was unable to covalently derivatise protein in an in vitro assay. It is thought that the ability to covalently derivatise protein enables some low-molecular-weight chemicals (LMWC) to induce allergic antibody-mediated responses that may cause asthma in people occupationally exposed to LMWC. The ability of DMAE to act as a skin sensitiser was tested in the murine local lymph node assay at 0, 3, 10, and 30% w/v (0, 33, 110, and 330 mmol/L). The test resulted in test:control ratios of 0, 1.93, 2.13, and 14.50 respectively. Typically, ratios greater than 3 are indicative of potential sensitisers; therefore, based on this test, DMAE was classified as a potential skin sensitizer. Human experiences with DMAE under normal handling precautions have not supported this result. Similarly, DMAE, evaluated in the guinea pig maximisation procedure, was without any clear evidence of skin sensitization **Metabolism:** DMAE is absorbed (either from the small intestine after oral dosing or from the bloodstream after injections), and rapidly transported to the liver where much of it is metabolised. DMAE is metabolised through the phospholipid cycle to produce phosphoryldimethylethanolamine and glycerophosphatidylcholine Pigs and rats dosed with cyprodenate maleate, the cyclohexylpropionic acid ester of DMAE, was found to be was well absorbed from the digestive tract and distributed to tissues and organs. Similarly, centrophenoxine (an ester of DMAE) was well absorbed after oral administration. After transport to the liver, a portion of centrophenoxine is converted to its constituent moieties, DMAE and p-chlorophenoxyacetic acid (PCPA), while the unmetabolised form was transported throughout the body by the circulatory system In humans, 33% of an injected 1 g (10 mmol) dose of DMAE was excreted unchanged. It was suggested that the remaining dose may have been demethylated to ethanolamine and entered into normal metabolic pathways. main concern with pharmaceutical drugs and dietary supplements are adverse effects. Long-term safety evidence is typically unavailable for many nootropic compounds. Racetams, piracetam and other compounds that are structurally related to piracetam, have few serious adverse effects and low toxicity, but there is little evidence that they enhance cognition in people having no cognitive impairments. Some nootropics can increase adrenaline levels in the body, producing effects similar to drinking large amounts of caffeine. Some drugs increase the number of certain chemicals (neurotransmitters), such as dopamine, that are released in parts of the brain associated with addiction. Research into how drugs work to stimulate the mind is still inconclusive, but early research suggests that drugs may act on different systems in the body simultaneously. One explanation is that it increases blood flow to the brain, allowing it to use more oxygen. Research into nootropics is still limited, so there are many uncertainties about the side effects the drugs may cause with continued use. Nootropics help mask fatigue, procrastination, or boredom, but they don't make people smarter, and their effects last as long as the drug remains in the body. Some of these drugs are addictive and have various side effects. It can be especially harmful to young people, as their brains continue to develop until their mid-twenties. In the United States, dietary supplements may be marketed if the manufacturer can show that the supplement is generally recognized as safe, and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertise health claims are illegal under US law. Nootropics are a heterogeneous group of drugs that affect the metabolism of neuronal cells in the central nervous system. They mainly improve cognitive function, especially in cases where there is damage or degeneration. Most of these substances do not have an immediate effect after a single administration and must be used for some length of time before there is a measurable improvement. They are used in acute, subacute, and chronic conditions of memory, consciousness, and learning disorders and as a supportive treatment in patients with Alzheimer's disease, schizophrenia, hyperkinetic disorder, or senile dementia. Nootropics are usually very well tolerated. Side effects are rare and typically mild, but some complications can occur. For example, people with cardiovascular disease should not use guarana. This is probably due to the relatively high caffeine content nootropics users should consider their state of health and mood before deciding to try a certain compound; however, if the recommended dosage is followed, no serious complications should occur. Because of their potential for improving memory and thinking and their easy availability, nootropics have particularly attracted the attention of college students, who call them "smart drugs". Because of the incomplete clinical evidence on their effectiveness, safety, and social consequences in the case of long-term use, especially with synthetic variants of these drugs, they cannot be recommended to healthy individuals who do not suffer from any cognitive dysfunction. There have not been sufficient experimental studies and results to support prophylactic use, even though the use of herbal supplements with nootropic effects has shown little risk of side effects and contraindications have been minimal. In any case, to be safe, none of these substances should be used during pregnancy or breastfeeding. Future research regarding nootropics should focus on experiments with more diverse human groups, whether in terms of age, health, gender, or weight. It should also mainly focus on young, healthy people, mostly university students, who use these substances a lot and obtain them, especially on the black market. Furthermore, already advanced methods based on neuroimaging assessment should be used more in experiments and studies to confirm or refute the potential beneficial effects. The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.
ISOPROPANOL & DIMETHYLETHANOLAMINE	Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS

Continued...

	include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

Acute Toxicity	✗	**Carcinogenicity**	✗
Skin Irritation/Corrosion	✗	**Reproductivity**	✗
Serious Eye Damage/Irritation	✓	**STOT - Single Exposure**	✗
Respiratory or Skin sensitisation	✗	**STOT - Repeated Exposure**	✗
Mutagenicity	✗	**Aspiration Hazard**	✗

Legend: ✗ ***– Data either not available or does not fill the criteria for classification***
✓ ***– Data available to make classification***

SECTION 12 Ecological information

Toxicity

FOLK ART GLITTERIFIC Paints

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

isopropanol

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	>1000mg/l	1
EC50	48h	Crustacea	7550mg/l	4
EC50(ECx)	24h	Algae or other aquatic plants	0.011mg/L	4
LC50	96h	Fish	>1400mg/L	4
EC50	96h	Algae or other aquatic plants	>1000mg/l	1

monoisobutanolamine

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	>103mg/l	2
EC50	48h	Crustacea	193mg/l	1
EC0(ECx)	48h	Crustacea	100mg/l	1
LC50	96h	Fish	100mg/l	1
EC50	96h	Algae or other aquatic plants	>103mg/l	2

dimethylethanolamine

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	35mg/l	1
EC0(ECx)	48h	Crustacea	62.5mg/l	1
EC50	48h	Crustacea	98.77mg/l	1
LC50	96h	Fish	88-131mg/l	1

Legend: ***Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data***

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
isopropanol	LOW (Half-life = 14 days)	LOW (Half-life = 3 days)
monoisobutanolamine	LOW	LOW
dimethylethanolamine	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
isopropanol	LOW (LogKOW = 0.05)
monoisobutanolamine	LOW (BCF = 330)
dimethylethanolamine	LOW (LogKOW = -0.9351)

Mobility in soil

Ingredient	Mobility
isopropanol	HIGH (Log KOC = 1.06)
monoisobutanolamine	MEDIUM (Log KOC = 2.196)
dimethylethanolamine	HIGH (Log KOC = 1.602)

Continued...

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	**DO NOT** allow wash water from cleaning or process equipment to enter drains. It may be necessary to collect all wash water for treatment before disposal. In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. Where in doubt contact the responsible authority. Recycle wherever possible. Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified. Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or Incineration in a licensed apparatus (after admixture with suitable combustible material). Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

SECTION 14 Transport information

Labels Required

	
Marine Pollutant	NO
HAZCHEM	•3YE

Land transport (ADG)

14.1. **UN number or ID number**	1263
14.2. **UN proper shipping name**	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base)
14.3. **Transport hazard class(es)**	Class: 3 Subsidiary Hazard: Not Applicable
14.4. **Packing group**	II
14.5. **Environmental hazard**	Not Applicable
14.6. **Special precautions for user**	Special provisions: 163 367 Limited quantity: 5 L

Air transport (ICAO-IATA / DGR)

14.1. **UN number**	1263
14.2. **UN proper shipping name**	Paint (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base)
14.3. **Transport hazard class(es)**	ICAO/IATA Class: 3 ICAO / IATA Subsidiary Hazard: Not Applicable ERG Code: 3L
14.4. **Packing group**	II
14.5. **Environmental hazard**	Not Applicable
14.6. **Special precautions for user**	Special provisions: A3 A72 A192 Cargo Only Packing Instructions: 364 Cargo Only Maximum Qty / Pack: 60 L Passenger and Cargo Packing Instructions: 353 Passenger and Cargo Maximum Qty / Pack: 5 L Passenger and Cargo Limited Quantity Packing Instructions: Y341 Passenger and Cargo Limited Maximum Qty / Pack: 1 L

Sea transport (IMDG-Code / GGVSee)

14.1. **UN number**	1263
14.2. **UN proper shipping name**	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base)
14.3. **Transport hazard class(es)**	IMDG Class: 3 IMDG Subsidiary Hazard: Not Applicable
14.4. **Packing group**	II
14.5 **Environmental hazard**	Not Applicable
14.6. **Special precautions for user**	EMS Number: F-E , S-E Special provisions: 163 367

Continued...

Limited Quantities	5 L

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
isopropanol	Not Available
monoisobutanolamine	Not Available
dimethylethanolamine	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
isopropanol	Not Available
monoisobutanolamine	Not Available
dimethylethanolamine	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

isopropanol is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australian Inventory of Industrial Chemicals (AIIC)
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

monoisobutanolamine is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australian Inventory of Industrial Chemicals (AIIC)

dimethylethanolamine is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australian Inventory of Industrial Chemicals (AIIC)

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes
Canada - NDSL	No (isopropanol; monoisobutanolamine; dimethylethanolamine)
China - IECSC	Yes
Europe - EINEC / ELINCS / NLP	Yes
Japan - ENCS	Yes
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	Yes
USA - TSCA	All chemical substances in this product have been designated as TSCA Inventory 'Active'
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	Yes
Legend:	***Yes = All CAS declared ingredients are on the inventory*** ***No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.***

SECTION 16 Other information

Revision Date	05/11/2024
Initial Date	05/11/2024

SDS Version Summary

Version	Date of Update	Sections Updated
2.1	05/11/2024	Composition / information on ingredients - Ingredients

Other information

Continued...

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- PC—TWA: Permissible Concentration-Time Weighted Average
- PC—STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ACGIH: American Conference of Governmental Industrial Hygienists
- STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit。
- IDLH: Immediately Dangerous to Life or Health Concentrations
- ES: Exposure Standard
- OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- LOAEL: Lowest Observed Adverse Effect Level
- TLV: Threshold Limit Value
- LOD: Limit Of Detection
- OTV: Odour Threshold Value
- BCF: BioConcentration Factors
- BEI: Biological Exposure Index
- DNEL: Derived No-Effect Level
- PNEC: Predicted no-effect concentration

- AIIC: Australian Inventory of Industrial Chemicals
- DSL: Domestic Substances List
- NDSL: Non-Domestic Substances List
- IECSC: Inventory of Existing Chemical Substance in China
- EINECS: European INventory of Existing Commercial chemical Substances
- ELINCS: European List of Notified Chemical Substances
- NLP: No-Longer Polymers
- ENCS: Existing and New Chemical Substances Inventory
- KECI: Korea Existing Chemicals Inventory
- NZIoC: New Zealand Inventory of Chemicals
- PICCS: Philippine Inventory of Chemicals and Chemical Substances
- TSCA: Toxic Substances Control Act
- TCSI: Taiwan Chemical Substance Inventory
- INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances